Vybor sredstv dlya dvoynoy antitrombotsitarnoy terapii pri ostrom koronarnom sindrome: mors ultima ratio

  • Authors: Averkov O.V1,2
  • Affiliations:
    1. ГБУЗ Городская клиническая больница №15 им. О.М.Филатова Департамента здравоохранения г. Москвы
    2. ГОУ ВПО Российский университет дружбы народов, Москва
  • Issue: Vol 15, No 10 (2013)
  • Pages: 75-80
  • Section: Articles
  • URL: https://journals.rcsi.science/2075-1753/article/view/93938
  • ID: 93938

Cite item

Full Text

Abstract

Двойная антитромбоцитарная терапия (ДАТТ), подразумевающая сочетание ацетилсалициловой кислоты (АСК) и блокатора P2Y12-рецепторов тромбоцитов, в последние годы обоснованно считается обязательным элементом лечения абсолютного большинства больных с любым вариантом острого коронарного синдрома (ОКС) [1–4]. До недавнего времени фактически единственным вариантом ДАТТ при ОКС было сочетание АСК и клопидогрела. Последний, имея свою серьезную доказательную базу, стал объектом сравнения в крупных исследованиях, посвященных оценке новых антиагрегантов с похожим механизмом действия, призванных вытеснить клопидогрел из ДАТТ. В большинстве своем эти исследования оказались успешными для новых блокаторов P2Y12-рецепторов тромбоцитов: при прямом сравнении клопидогрел уступил новым представителям своего класса (тиенопиридинов) прасугрелу и тикагрелору, не являющимся тиенопиридинами. В чем выразились преимущества новых препаратов и каковы основания для их предпочтительного использования вместо клопидогрела у больных с ОКС? Ответ на этот вопрос – в тексте, изложенном далее.

About the authors

O. V Averkov

ГБУЗ Городская клиническая больница №15 им. О.М.Филатова Департамента здравоохранения г. Москвы; ГОУ ВПО Российский университет дружбы народов, Москва

References

  1. Steg G, James D.K, Atar D et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J 2012; 33: 2569–619.
  2. O’Gara P.T, Kushner F.G, Ascheim D.D et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013: published online before print December 17, 2012; 10.1161/CIR.0b013e3182742c84
  3. Hamm C.W, Bassand J.P, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
  4. Wright R.S, Anderson J.L, Adams C.D et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA2007Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2011; 57: e215–367.
  5. Thygesen K, Alpert J.S, Jaffe A.S et al. Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020–35.
  6. Omland T, Pfeffer M.A, Solomon S.D et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013; doi: 10.1016/j.jacc.2012.12.026
  7. De Lemos J.A, Drazner M.H, Omland T et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503–12.
  8. Saunders J.T, Nambi V, de Lemos J.A et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation 2011; 123: 1367–76.
  9. Brauwald E, Morrow D.A. Unstable Angina: Is It Time for a Requiem? Circulation 2013; 127: 2452–7.
  10. Eikelboom J.W, Mehta S.R, Anand S.S et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774–82.
  11. Budaj A, Eikelboom J.W, Mehta S.R et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009; 30: 655–61.
  12. Mehran R, Pocock S.J, Stone G.W et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457–66.
  13. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
  14. Baigent C, Collins R, Appleby et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparision of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316: 1337–43.
  15. Cairns J.A, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–75.
  16. The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001; 345: 494–502.
  17. Sabatine M.S, Cannon C.P, Gibson et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89.
  18. COMMIT collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo - controlled trial. Lancet 2005; 366: 1607–21.
  19. Wiviott S.D, Braunwald E, Mc Cabe C.H et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
  20. Roe M.T, Armstrong P.W, Fox K.A et al. TRILOGY ACS Investigators. Prasugrel versus clopidogrel for the acute coronary syndromes without revascularization. N Engl J Med 2012; 367 (4): 1297–309.
  21. Wallentin L, Becker R.C, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361. doi: 10.1056/NEJMoa0904327.
  22. Serebruany V.L, Atar D. The PLATO trial: do you believe in magic? Eur Heart J 2010; 31: 764–7.
  23. Di Nicolantonio J.J, Serebruany V.L. Exploring the ticagrelor - statin interplay in the PLATO trial. Cardiology 2013; 124: 105–7.
  24. Shneider D.J. Mechanisms Potentially contributing to the reduction in Mortality Associated with ticagrelor therapy. J Am Coll Cardiol 2011; 57 (6): 685–7.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies